Gradually making its way into legality across the United Sates, marijuana has been a major source of national controversy over the past few years. However, cannabis has many advantages that shouldn’t be overlooked. One of the major benefits of cannabis is its ability to treat many mental and physical health conditions. Oklahoma City cannabis users with certain conditions can be recommended CBD oil, which comes from the cannabis plant.

CBD, or cannabidiol, does not cause the feeling of being “high.” Rather, it has helped some people with medical conditions lessen their symptoms. The chemical in cannabis that causes the “high” feeling is THC, which is not in cannabidiol, meaning that CBD users will not be getting the “high.”

In June 2018, the FDA approved the drug Epidiolex, which is CBD oil, for the treatment of two rare epileptic disorders: Lennox-Gastaut syndrome and Dravet syndrome. People living with these conditions suffer from prolonged seizures that can be difficult to treat, and Epidiolex hitting the market soon could mean more patients using medical Oklahoma City cannabis based on state marijuana laws. Medical cannabis is legal in Oklahoma for the treatment of a select few conditions, including Dravet and Lennox-Gastaut syndromes.

In several studies of patients with Dravet or Lennox-Gastaut syndromes, CBD has reduced the frequency and severity of seizures dramatically. One study led by Dr. Orrin Devinsky of NYU Langone’s Comprehensive Epilepsy Center found that patients taking Epidiolex had about 40% fewer seizures than when they weren’t taking the drug. This trial was done in May and its positive results could have influenced the FDA’s decision to legalize the drug in June.

Patients with Lennox-Gastaut or Dravet syndromes in Oklahoma City have a new treatment on the horizon. Although not yet available for purchase at dispensaries, Epidiolex getting FDA-approved is a win for Oklahoma City cannabis supporters suffering from epilepsy. Stay up-to-date on Epidiolex to know when the drug will hit the market.